

Turku University Hospital, Department of Oncology and Radiotherapy, Hämeentie 11, Post Box 52, 20521 Turku, Finland.

Tel.: +358-2-3130729, +358449785272

Fax: +358-2-3137175

Mail: kalle.mattila@tyks.fi

Education and Training:

Turku University, Faculty of Medicine, Medical Doctor 21.5.2008.

Turku University, Specialist in Oncology and Radiotherapy 28.11.2018

Certification: License Number 03203675685

Professional Experience:

Specialist, Oncology and Radiotherapy, Turku University Hospital and Fican West Cancer Centre 1.1.2019 -

Resident, Oncology and Radiotherapy, Turku University Hospital. 1.4.2013-31.12.2018

Resident, Surgery, Turku University Hospital. 1.8.2012-31.3.2013

General practitioner, Turku Health Services. 1.2.2012-8.7.2012

Resident, Surgery, Turku University Hospital, Salo. 1.6.2010-31.1.2012

Resident, Surgery, Savonlinna Central Hospital. 3.11.2008-31.5.2010

General Practitioner, Vantaa Health Services. 21.4.2008-26.10.2008.

Special interest in melanoma and non-melanoma skin cancers, urogenital cancers, and clinical trials.

Vice-chairman of the Finnish Melanoma Group

Member of the Finnish Genitourinary Cancer Group (FIGUG)

Member of Suomen Onkologiyhdistys

Member of the ASCO

Clinical Trial Experience from phase I-III clinical trials:

ICH GCP 18.5.2020

National Coordinating Investigator in clinical trials:

Prostate cancer: MK-3476-991

Melanoma: CA045-001

Principal Investigator in clinical trials at Turku University Hospital and Fican West Cancer Centre:

Prostate cancer: MK-3476-991

Melanoma: CA209-76K, CA045-001

Renal cancer: XL184-313, MK-6482-012

Subinvestigator in clinical trials:

Melanoma: Finnish Melanoma Group Cobra-trial EudraCT Number 2013-000280-84 ML28882, EORTC protocol 1325-MG/MK-3475-054-01, BMS CA209-401, BMS CA224-047, Combi-APlus

Urothelial cancer: MK-3475-057, WO30070, CA017-078

Renal cancer: MK-3475-564, Eisai E7080-G000-218

Prostate cancer: MK-3475-199, Talapro-2, Talapro-3

Phase I trials: BI 1280.18 EudraCT Number 2016-003142-85, Matins, Matins Renacol

Publications:

1. Mattila K, Raanta P, Lahtela V, Pyrhonen S, Koskivuo I, Vihinen P. Long-term survival of stage IV melanoma patients treated with BOLD combination chemotherapy and intermediate-dose subcutaneous interferon-alpha. *Anticancer Res.* 2018; 38:6393-6397.
2. Mattila K, Mäkelä S, Hernberg M, Vihinen P. Immuuniaktivaation vapauttajien haittavaikutukset Miten tunnistaa ja hoidan? *Suomen Lääkärilehti.* 2018; 6:373-376
3. Vihinen P, Mattila K, Mäkelä S, Hernberg M, Koivunen J. Immuno-onkologisten lääkkeiden käyttö, haittavaikutuksen ja niiden hoito. *Duodecim.* 2019; 135:2095-103.
4. Mattila KE, Vihinen P, Ramadan S, et al. Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. *Acta Oncol.* 2020; 59:310-314.
5. Malaspina S, Oikonen V, Kuisma A, et al. Kinetic analysis and optimisation of (18)F-rhPSMA-7.3 PET imaging of prostate cancer. *Eur J Nucl Med Mol Imaging.* 2021; 48:3723-3731.
6. Mattila K, Vihinen P, Skyttä T, et al. Ihomelanooman onkologinen hoito päivittyi. *Duodecim.* 2021;137(7):721-8
7. Karlsson A, Ellonen A, Irjala H, et al. Impact of deep learning-determined smoking status on mortality of cancer patients: Never too late to quit. *ESMO Open.* 2021; 6:100175.

8. Mattila KE, Laajala TD, Tornberg SV, et al. A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. *Sci Rep.* 2021; 11:8650-9.
9. Tulokas SKA, Kohtamaki LM, Makela SP, et al. Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: Results of 60 patients treated in finland during 2007-2018. *Melanoma Res.* 2021; 31:456-463.